Prevalence and prognostic influence of genomic changes of EGFR pathway markers in synovial sarcoma
- 15 January 2011
- journal article
- research article
- Published by Wiley in Journal of Surgical Oncology
- Vol. 103 (8) , 773-781
Abstract
Background: We aimed to study the prevalence and prognostic influence of epidermal growth factor receptor (EGFR) and its downstream effectors in synovial sarcoma (SS).Objectives and Methods: The tissue blocks from 30 patients were obtained. Expression of EGFR and phosphatase and tensin homolog (PTEN) were examined by immunohistochemistry, and mutation status of v‐Ki‐ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) exon 2, V‐raf murine sarcoma viral oncogene homolog B1 (BRAF) exon 15, phosphoinositide‐3‐kinase, catalytic, alpha polypeptide (PI3KCA) exons 9, 20, and PTEN exons 5–9 were analyzed by direct sequencing.Results: EGFR overexpression and PTEN deletion were found in 63.3% and 46.7% of patients. Sequence analysis failed to demonstrate mutations of KRAS and BRAF. However, an E545A point mutation in exon 9 of PI3KCA was found in 2 of the 30 (6.7%) cases and 4 point mutations in exon 5 (E99K, D106N), intro 6 to exon 7 (AATA(G)), and exon 9 (A359T) of PTEN were found in 2 of the 30 (6.7%) cases. PTEN loss was significantly more frequent in cases of trunk tumors, and the overexpression of EGFR was significantly more prevalent in patients who were 35 or older.Conclusions: PTEN deletion was associated with poor survival. J. Surg. Oncol. 2011;103:773–781.Keywords
Funding Information
- Department of Health, Taiwan
- Center of Excellence for Cancer Research at Taipei Veterans General Hospital (DOH99-TD-C-111-007)
- Taipei Veterans General Hospital (100DHA0100416)
- Taiwan Clinical Oncology Research Foundation
This publication has 43 references indexed in Scilit:
- Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapyNature Genetics, 2010
- The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patientsAnnals of Oncology, 2010
- Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor–Targeted Therapy in Metastatic Colorectal CancerJNCI: Journal of the National Cancer Institute, 2009
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaNew England Journal of Medicine, 2009
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal CancerNew England Journal of Medicine, 2009
- PTEN and the PI3-Kinase Pathway in CancerAnnual Review of Pathology: Mechanisms of Disease, 2009
- Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic AnalysesScience, 2008
- Comprehensive genomic characterization defines human glioblastoma genes and core pathwaysNature, 2008
- SYT–SSXGene Fusion as a Determinant of Morphology and Prognosis in Synovial SarcomaNew England Journal of Medicine, 1998
- Synovial sarcoma outcome following conservation surgery and radiotherapyRadiotherapy and Oncology, 1994